Trial Investigating Pembrolizumab for Hormone-Sensitive Prostate Cancer Discontinued
The pembrolizumab combination was not associated with an improvement in overall survival or radiographic progression-free survival.
The pembrolizumab combination was not associated with an improvement in overall survival or radiographic progression-free survival.
Metastasis-directed therapy can delay initiation of systemic therapy in patients with solitary oligorecurrent metastatic lesion
Novavax vaccine booster update; over-the-counter hearing aids; Priority Review for a castration-resistant prostate cancer combination treatment; first gene therapy approved for beta-thalassemia; FDA urges repeat at home COVID-19 testing to reduce risk of missing infection.
The sNDA is supported by data from the phase 3 PROpel trial which included adults with mCRPC in the first-line setting.
The approval was based on data from the phase 3 ARASENS trial.
The LEAP-002 study evaluated pembrolizumab plus lenvatinib in patients with uHCC; the KEYNOTE-921 study evaluated pembrolizumab plus docetaxel in patients with mCRPC.
Increase in screening differed by age, with 19.4 percent increase for those aged 50 to 54 and 31.6 percent increase for those aged 70 to 75
Significant reduction seen in risk of prostate cancer progression for enzalutamide plus AS versus active surveillance alone
However, association does not hold for nondairy calcium intake